Metabolic disease

Metabolic diseaseObesity has reached epidemic proportions and is associated with widespread health problems.

Chronic high-caloric intake and lack of exercise result in the storage of excess energy as lipid in body fat depots. The increases in body fat then trigger metabolic and inflammatory responses that lead to insulin resistance, type 2 diabetes, cardiovascular disease and increased risk of cancer.

Although changes in lifestyle are a first-line treatment option, most patients require additional therapeutic intervention.

DDB studies target G protein-coupled receptors as well as cytokine receptors, and focus on three main avenues for therapy of obesity and diabetes:

  • to modulate adipocyte metabolism
  • to activate glucose disposal in skeletal muscle
  • to enhance and preserve the release of insulin from pancreatic islets
  • to mitigate the harmful effects of diabetes on the cardiovascular system


Research laboratories

Analytical & Structural Neuropharmacology Cellular & Molecular Metabolism
Dr Celine Valant Dr David Thal Prof Arthur Christopoulos   Prof Mark Febbraio
Endocrine & Neuropharmacology Heart Failure Pharmacology
Dr Katie Leach Dr Karen Gregory    Prof Rebecca Ritchie
Metabolic GPCR Biology Molecular & Translational Drug Discovery
Prof Patrick Sexton A/Prof Denise Wootten    Dr Chris Langmead
Receptor Transducer Coupling 
Dr Sebastian Furness